H.C. Wainwright lowered the firm’s price target on iTeos Therapeutics (ITOS) to $21 from $46 and keeps a Buy rating on the shares. The firm removed expected revenue from inupadenant in lung cancer following the interim data.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS: